Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Wattmo C, Paulsson E, Minthon L, Londos E.

Clin Interv Aging. 2013;8:329-39. doi: 10.2147/CIA.S40087. Epub 2013 Mar 20.

PMID:
23682212
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Wattmo C, Wallin AK, Minthon L.

BMC Neurol. 2012 Nov 5;12:134. doi: 10.1186/1471-2377-12-134.

PMID:
23126532
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
[PubMed - indexed for MEDLINE]
4.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

PMID:
18597574
[PubMed - indexed for MEDLINE]
Free Article
5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID:
16437532
[PubMed - indexed for MEDLINE]
6.

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

Wattmo C, Wallin ÅK, Londos E, Minthon L.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):63-72. doi: 10.1097/WAD.0b013e3181f5dd97.

PMID:
20847636
[PubMed - indexed for MEDLINE]
7.

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.

Eur J Clin Pharmacol. 2011 Nov;67(11):1147-57. doi: 10.1007/s00228-011-1064-x. Epub 2011 Jun 1.

PMID:
21630031
[PubMed - indexed for MEDLINE]
8.

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

Aguglia E, Onor ML, Saina M, Maso E.

Curr Med Res Opin. 2004 Nov;20(11):1747-52.

PMID:
15537474
[PubMed - indexed for MEDLINE]
9.

Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

Wattmo C, Wallin AK, Londos E, Minthon L.

Gerontologist. 2011 Feb;51(1):17-27. doi: 10.1093/geront/gnq050. Epub 2010 Jun 20.

PMID:
20562471
[PubMed - indexed for MEDLINE]
10.

Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN.

Am J Geriatr Pharmacother. 2006 Jun;4(2):154-60.

PMID:
16860262
[PubMed - indexed for MEDLINE]
11.

Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.

Arch Gerontol Geriatr Suppl. 2004;(9):297-307.

PMID:
15207427
[PubMed - indexed for MEDLINE]
12.

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.

Dement Geriatr Cogn Disord. 2005;19(4):189-95. Epub 2005 Jan 25.

PMID:
15677866
[PubMed - indexed for MEDLINE]
13.

Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.

Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R.

J Med Econ. 2009 Jun;12(2):98-103. doi: 10.3111/13696990903004039.

PMID:
19492974
[PubMed - indexed for MEDLINE]
14.

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.

Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P; Donepezil MSAD Study Investigators Group.

J Am Geriatr Soc. 2003 Jun;51(6):737-44. Erratum in: J Am Geriatr Soc. 2003 Sep;51(9):1331.

PMID:
12757558
[PubMed - indexed for MEDLINE]
15.

Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.

Crowell TA, Paramadevan J, Abdullah L, Mullan M.

J Geriatr Psychiatry Neurol. 2006 Mar;19(1):13-5.

PMID:
16449754
[PubMed - indexed for MEDLINE]
16.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
[PubMed - indexed for MEDLINE]
17.

The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

Thompson S, Lanctôt KL, Herrmann N.

Expert Opin Drug Saf. 2004 Sep;3(5):425-40. Review.

PMID:
15335298
[PubMed - indexed for MEDLINE]
18.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
[PubMed - indexed for MEDLINE]
19.

Effective pharmacological management of Alzheimer's disease.

Atri A.

Am J Manag Care. 2011 Nov;17 Suppl 13:S346-55. Review.

PMID:
22214392
[PubMed - indexed for MEDLINE]
Free Article
20.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk